The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with hydrochlorothiazide on pulse wave velocity and central blood pressure
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376463" target="_blank" >RIV/00216208:11110/18:10376463 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/18:10376463
Result on the web
<a href="https://doi.org/10.5603/KP.a2017.0240" target="_blank" >https://doi.org/10.5603/KP.a2017.0240</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5603/KP.a2017.0240" target="_blank" >10.5603/KP.a2017.0240</a>
Alternative languages
Result language
angličtina
Original language name
The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with hydrochlorothiazide on pulse wave velocity and central blood pressure
Original language description
Background and aim: The aim of the study was to establish the effect of valsartan and combination of valsartan and hydrochlorothiazide (HCTZ) on pulse wave velocity (PWV) and central blood pressure (CBP) in a large population of patients with mild to moderate arterial hypertension. Methods: This was an international, multicentre, open-label, prospective trial. After one week of washout in previously treated patients, 74 subjects were treated with valsartan or valsartan combined with HCTZ for 16 weeks according to the protocol. Naive patients received the treatment immediately. During the active treatment, four visits were planned for each patient to obtain data for the primary and secondary efficacy. At the beginning and at the end of the study PWV and CBP were determined with central arterial pressure waveform analysis (SphygmoCor (R), Atcor Medical). This study is registered with clinicaltrialsregister.eu, EudraCT number 2012-005129-57. Results: The results of the present VICTORY trial showed that valsartan and combination of valsartan and HCTZ effectively reduced the brachial blood pressure in patients with mild to moderate arterial hypertension as well as PWV, central systolic blood pressure and central diastolic blood pressure. The effects on the augmentation index were not statistically significant. Conclusions: Valsartan and valsartan/HCTZ improve arterial stiffness in patients with mild to moderate hypertension.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Kardiologia Polska
ISSN
0022-9032
e-ISSN
—
Volume of the periodical
76
Issue of the periodical within the volume
2
Country of publishing house
PL - POLAND
Number of pages
10
Pages from-to
328-337
UT code for WoS article
000425965300004
EID of the result in the Scopus database
2-s2.0-85042069634